Jones Trading Initiates Coverage On Intellia Therapeutics With Buy Rating, Announces Price Target of $41
Intellia Therapeutics Analyst Ratings
JonesTrading Initiates Intellia Therapeutics(NTLA.US) With Buy Rating, Announces Target Price $41
JonesTrading analyst Debanjana Chatterjee initiates coverage on $Intellia Therapeutics(NTLA.US)$ with a buy rating, and sets the target price at $41.According to TipRanks data, the analyst has a
Intellia Therapeutics: A Bullish Outlook on Gene Editing Innovation and Market Potential
Reported Earlier Intellia Therapeutics To Present Data From The Phase 2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2024 ACAAI Annual Scientific Meeting; To Host Investor Webcast On October 28, At 8:00 A.m. ET
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com